World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
55
Citations
11151
World Ranking
15036
National Ranking
6293

Ezio Bonvini publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Ezio Bonvini sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 206 publications — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Ezio Bonvini D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Ezio Bonvini sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 55 D-Index — 25th percentile

25% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Ezio Bonvini is affiliated with the Center for Biologics Evaluation and Research in the United States. Their primary field of study is Medicine, with a focus on Oncology, Immunology, Hematology, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

Their research encompasses a range of topics including:

  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Acute Myeloid Leukemia Research
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • HER2/EGFR in Cancer Research

Some of their recent papers include:

  • "Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer," 2021, published in JAMA Oncology
  • "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia," 2020, published in Blood
  • "Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer," 2020, published in Molecular Cancer Therapeutics
  • "Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial," 2022, published in Journal for ImmunoTherapy of Cancer
  • "Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule," 2020, published in Cell Reports Medicine

Frequent co-authors working alongside Ezio Bonvini include:

  • Paul A. Moore
  • Deryk Loo
  • Juniper A. Scribner
  • Thomas Son
  • James Tamura

Their publications commonly appear in several venues, indicating areas of recurring contribution:

  • Cancer Research (9 publications)
  • Blood (6 publications)
  • Molecular Cancer Therapeutics (3 publications)
  • Journal for ImmunoTherapy of Cancer (2 publications)
  • Journal of Clinical Oncology (2 publications)

Best Publications

  • CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

    Robbie G. Majzner;Johanna L. Theruvath;Anandani Nellan;Sabine Heitzeneder

  • Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors

    Jeffrey B. Stavenhagen;Sergey Gorlatov;Nadine Tuaillon;Christopher T. Rankin

  • Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions

    Adam M. Boruchov;Glenn Heller;Maria-Concetta Veri;Ezio Bonvini

  • Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

    Paul A. Moore;Wenjun Zhang;G. Jonah Rainey;Steve Burke

  • Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

    Deryk Loo;Ralph F. Alderson;Francine Z. Chen;Ling Huang

  • Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells

    Kavita M. Dhodapkar;Jacob L. Kaufman;Marc Ehlers;Devi K. Banerjee

  • Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

    Syd Johnson;Stephen Burke;Ling Huang;Sergey Gorlatov

  • Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

    Hope S. Rugo;Seock Ah Im;Fatima Cardoso;Javier Cortés

  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

    Geoffrey L. Uy;Ibrahim Aldoss;Matthew C. Foster;Peter H. Sayre

  • Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

    Jeffrey L Nordstrom;Sergey Gorlatov;Wenjun Zhang;Yinhua Yang

  • dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats

    Victoriano Baladrón;María José Ruiz-Hidalgo;María Luisa Nueda;María José M. Díaz-Guerra

  • Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization

    Maria-Concetta Veri;Sergey Gorlatov;Hua Li;Steve Burke

  • Therapeutic Control of B Cell Activation via Recruitment of Fcγ Receptor IIb (CD32B) Inhibitory Function With a Novel Bispecific Antibody Scaffold

    Maria-Concetta Veri;Stephen Burke;Ling Huang;Hua Li

  • Notch-1 Controls the Expression of Fatty Acid-activated Transcription Factors and Is Required for Adipogenesis

    Carmen Garcés;M.J. Ruiz-Hidalgo;Jaime Font de Mora;Crystal Park

  • A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

    Gurunadh R. Chichili;Ling Huang;Hua Li;Steve Burke

  • Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.

    Muneera Al-Hussaini;Michael P. Rettig;Julie K. Ritchey;Darja Karpova

  • Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-associated dlk

    Carmen Garcés;María José Ruiz-Hidalgo;Ezio Bonvini;Julia Goldstein

  • CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma

    Christopher T. Rankin;Maria-Concetta Veri;Sergey Gorlatov;Nadine Tuaillon

  • Tumor Necrosis Factor {alpha} (TNF-{alpha}) Activates Jak1/Stat3-Stat5B Signaling through TNFR-1 in Human B Cells

    Sebastiano Miscia;Marco Marchisio;Alfredo Grilli;Valentina Di Valerio

  • KOVALENT BUNDNE DIABODIES, DER HAR IMMUNREAKTIVITET MED PD-1 OG LAG-3, OG FREMGANGSMÅDER TIL BRUG DERAF

    Bonvini Ezio;Johnson Leslie S;Shah Kalpana;Koenig Scott

Frequent Co-Authors

Scott Koenig
Scott Koenig MacroGenics (United States)
Paul A. Moore
Paul A. Moore MacroGenics (United States)
Syd Johnson
Syd Johnson AstraZeneca (United Kingdom)
Jon M. Wigginton
Jon M. Wigginton Bristol-Myers Squibb (Germany)
John F. DiPersio
John F. DiPersio Washington University in St. Louis
Ronald L. Wilder
Ronald L. Wilder National Institutes of Health
Douglas H. Smith
Douglas H. Smith University of Pennsylvania
Bob Löwenberg
Bob Löwenberg Erasmus MC
Fabio Ciceri
Fabio Ciceri Vita-Salute San Raffaele University
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Biology or Biochemistry opens doors to a wide variety of healthcare and science careers. Many students are now considering flexible online programs to begin or advance their education in related fields. For example, if you’re interested in diagnostic imaging and wish to enter healthcare quickly, online rad tech programs provide affordable and accessible options to earn an associate degree.

If nutrition and patient wellness interest you, pursuing one of the top dietitian masters programs can lead to a rewarding career as a registered dietitian. For those seeking entry-level roles in healthcare, there are medical assistant classes online with financial aid that offer flexible schedules and support for managing tuition costs.

Career advancement is also possible for certified medical assistants. Programs such as cma to lpn bridge programs online can help you transition toward licensed practical nursing, expanding your clinical responsibilities and earning potential. Whichever path you choose, online healthcare programs make it easier to match your studies to your career goals.

Best Scientists Citing Ezio Bonvini

Trending Scientists

Recently Published Articles